Polymorphic metabolism of beta-adrenoceptor antagonists

Area of Science:

• Pharmacogenomics
• Drug Metabolism
• Cardiovascular Pharmacology

Background:

• Most beta-adrenoceptor blockers are extensively metabolized via oxidation.
• Debrisoquine metabolism is a well-established marker for genetic polymorphisms in drug metabolism.
• Individual variability in drug response is often linked to genetic differences in metabolic enzyme activity.

Purpose of the Study:

• To review the evidence for debrisoquine-type polymorphism in beta-blocker metabolism.
• To investigate the impact of genetic oxidation status on the pharmacokinetics and pharmacodynamics of metoprolol, bufuralol, and propranolol.
• To explore potential clinical implications, such as altered dosing requirements and drug interactions.

Main Methods:

• Review of existing literature on debrisoquine phenotype and beta-blocker metabolism.
• Analysis of pharmacokinetic data (AUC, half-life) for metoprolol, bufuralol, and propranolol in poor metabolizers (PM) and extensive metabolizers (EM) of debrisoquine.
• Correlation of oxidation phenotype with the intensity and duration of beta-adrenoceptor blockade.

Main Results:

• Poor metabolizers (PM) of debrisoquine exhibit significantly greater AUC and half-life for metoprolol, indicating impaired alpha-hydroxylation and O-dealkylation.
• Bufuralol also shows higher AUC and half-life in PM subjects, with affected hydroxylation at the 1 and 4 positions.
• Metoprolol's beta-blockade intensity and duration correlate with oxidation phenotype; PMs may require once-daily dosing, while EMs may need twice-daily dosing.
• Propranolol's AUC is not related to debrisoquine phenotype, suggesting unaffected major metabolic pathways.
• Vomiting after bufuralol administration is more frequent in PM subjects.

Conclusions:

• Genetic polymorphism in debrisoquine metabolism influences the pharmacokinetics and pharmacodynamics of certain beta-blockers, notably metoprolol and bufuralol.
• Oxidation status significantly affects metoprolol dosing requirements, with PMs potentially benefiting from less frequent administration.
• While propranolol's blockade intensity may not be affected, further investigation into toxicity reports in PM subjects is warranted.
• Metabolic interactions between drugs utilizing the same enzyme system, like debrisoquine and bufuralol, are possible and require consideration.